Zafgen climbs on Phase II HIAO results

Zafgen Inc. (NASDAQ:ZFGN) gained $6.65 (21%) to $38.31 after it said beloranib met the primary endpoint of weight reduction in a Phase II trial to treat adults with hypothalamic injury associated obesity (HIAO).

In the 14-patient trial, subjects receiving twice-weekly subcutaneous injections of 1.8 mg beloranib had a mean weight loss of 3.4 kg and 6.2 kg after four and eight weeks of treatment, respectively, compared to 0.3 kg in patients who received placebo for four weeks (p=0.01). HIAO is a rare condition resulting from damage to the hypothalamus following resection of CNS tumors. ...